Serum but not cerebrospinal fluid levels of allantoin are increased in de novo Parkinson’s disease

[1]  Hongtao Chang,et al.  Dose-response meta-analysis on urate, gout, and the risk for Parkinson’s disease , 2022, npj Parkinson's Disease.

[2]  U. Kang,et al.  Dysautonomia and REM sleep behavior disorder contributions to progression of Parkinson’s disease phenotypes , 2022, npj Parkinson's Disease.

[3]  D. Mozaffarian,et al.  Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. , 2021, JAMA.

[4]  J. Siuda,et al.  The Influence of Serum Uric Acid Level on Non-Motor Symptoms Occurrence and Severity in Patients with Idiopathic Parkinson’s Disease and Atypical Parkinsonisms—A Systematic Review , 2021, Medicina.

[5]  E. Růžička,et al.  Patients with REM sleep behavior disorder have higher serum levels of allantoin. , 2021, Parkinsonism & related disorders.

[6]  Demis A. Kia,et al.  Mendelian Randomisation Finds No Causal Association between Urate and Parkinson's Disease Progression , 2021, Movement disorders : official journal of the Movement Disorder Society.

[7]  M. Stamelou,et al.  Serum uric acid level as a putative biomarker in Parkinson's disease patients carrying GBA1 mutations: 2-Year data from the PPMI study. , 2021, Parkinsonism & related disorders.

[8]  E. Růžička,et al.  Clinical characteristics of newly dia gnosed Parkinson’s disease patients included in the longitudinal BIO-PD study , 2020, Česká a slovenská neurologie a neurochirurgie.

[9]  Zhichun Chen,et al.  Autonomic dysfunction in Parkinson’s disease: Implications for pathophysiology, diagnosis, and treatment , 2019, Neurobiology of Disease.

[10]  J. Závada,et al.  Rapid and reliable HILIC-MS/MS method for monitoring allantoin as a biomarker of oxidative stress. , 2019, Analytical biochemistry.

[11]  E. Růžička,et al.  Relations of non-motor symptoms and dopamine transporter binding in REM sleep behavior disorder , 2019, Scientific Reports.

[12]  K. Double,et al.  Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease , 2019, Aging cell.

[13]  Yong Cheng,et al.  Oxidative Stress in Parkinson's Disease: A Systematic Review and Meta-Analysis , 2018, Front. Mol. Neurosci..

[14]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[15]  C. Tanner,et al.  Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[16]  A. Lees,et al.  Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease , 2017, JAMA neurology.

[17]  A. Dagher,et al.  Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression , 2017, Brain : a journal of neurology.

[18]  Zhaokun Ma,et al.  Serum uric acid levels in patients with Parkinson’s disease: A meta-analysis , 2017, PloS one.

[19]  T. Nikolai,et al.  Montreal cognitive assessment (MoCA): Normative data for old and very old Czech adults , 2017, Applied neuropsychology. Adult.

[20]  Stefan Enroth,et al.  Effects of Long-Term Storage Time and Original Sampling Month on Biobank Plasma Protein Concentrations , 2016, EBioMedicine.

[21]  S. Factor,et al.  Potential mechanisms for low uric acid in Parkinson disease , 2016, Journal of neural transmission.

[22]  G. Deuschl,et al.  MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[23]  H. Sies,et al.  Oxidative stress: a concept in redox biology and medicine , 2015, Redox biology.

[24]  M. T. Pellecchia,et al.  Is serum uric acid related to non-motor symptoms in de-novo Parkinson's disease patients? , 2014, Parkinsonism & related disorders.

[25]  Liang Shen,et al.  Low uric acid levels in patients with Parkinson's disease: evidence from meta-analysis , 2013, BMJ Open.

[26]  T. Friede,et al.  Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort , 2013, Neurology.

[27]  S. Cipriani,et al.  Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration , 2012, Proceedings of the National Academy of Sciences.

[28]  S. Cipriani,et al.  Urate and Its Transgenic Depletion Modulate Neuronal Vulnerability in a Cellular Model of Parkinson's Disease , 2012, PloS one.

[29]  Koen Van Laere,et al.  EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2 , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  J. Fleming,et al.  A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking , 2009, Neurology.

[31]  C. Tanner,et al.  Urate as a predictor of the rate of clinical decline in Parkinson disease. , 2009, Archives of neurology.

[32]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[33]  A. Lang,et al.  Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. , 2008, Archives of neurology.

[34]  Piero Calvini,et al.  The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[35]  V. Mužáková,et al.  Monitoring of antioxidant properties of uric acid in humans for a consideration measuring of levels of allantoin in plasma by liquid chromatography. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[36]  Y. Özkan,et al.  Evaluation of allantoin levels as a new marker of oxidative stress in Behçet's disease , 2006, Scandinavian journal of rheumatology.

[37]  H. Pfister,et al.  Urate Oxidation in CSF and Blood of Patients with Inflammatory Disorders of the Nervous System , 2004, Nucleosides, nucleotides & nucleic acids.

[38]  Johan Marinus,et al.  Assessment of autonomic dysfunction in Parkinson's disease: The SCOPA‐AUT , 2004, Movement disorders : official journal of the Movement Disorder Society.

[39]  B F Becker,et al.  Oxidative stress in bacterial meningitis in humans , 2002, Neurology.

[40]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[41]  Eka Swadiansa.  The hypothesis , 1990 .

[42]  B. Halliwell,et al.  Measurement of allantoin and uric acid in human body fluids. A potential index of free-radical reactions in vivo? , 1987, The Biochemical journal.

[43]  R. Doty,et al.  Development of the university of pennsylvania smell identification test: A standardized microencapsulated test of olfactory function , 1984, Physiology & Behavior.

[44]  B. Ames,et al.  Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Kanďár.  The ratio of oxidized and reduced forms of selected antioxidants as a possible marker of oxidative stress in humans. , 2016, Biomedical chromatography : BMC.

[46]  J. Kaye,et al.  Uric acid as a CNS antioxidant. , 2010, Journal of Alzheimer's disease : JAD.

[47]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[48]  B. Halliwell,et al.  Action of biologically-relevant oxidizing species upon uric acid. Identification of uric acid oxidation products. , 1990, Chemico-biological interactions.